Skip to Content

'
Karen E Hoffman, M.D., M.H.Sc., M.P.H.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd
Unit Number: 1202
Houston, TX 77030
Room Number: ACBP1.2847

Education & Training

Degree-Granting Education

2008 Harvard School of Public Health, Boston, MA, MPH, Concentration in Health Care Management
2006 Duke University, Durham, NC, M.H.Sc., Clinical Research
2004 Duke University, Durham, NC, MD, Medicine
1997 University of Virginia, Charlottesville, VA, BA, Biology

Postgraduate Training

7/2005-6/2009 Clinical Residency, Radiation Oncology, Harvard Radiation Oncology Program, Boston, MA, Jay Harris, M.D.
7/2004-7/2005 Clinical Residency, Transitional Medicine, Georgetown University Hospital, Washington, DC, and Fairfax INOVA Hospital, Fairfax, VA

Board Certifications

6/2010 American Board of Radiology

Experience/Service

Institutional Committee Activities

Member, Clinical Research Committee (CRC) 4, 1/2013-present
Member, Clinical Research Committee (CRC) 1, 9/2010-8/2012

Honors and Awards

2012 The Red Journal's Outstanding Reviewer Award
2011-2013 Scholar, Comparative Effectiveness Research on Cancer in Texas
2010 The Dr. Karen E. Hoffman Radiation Therapy Education Fund/Endowment
2008 Clinical Research Fellowship, Radiation Therapy Oncology Group/American College of Radiology
2007 49th Annual Meeting Basic Science Travel Grant, American Society of Therapeutic Radiology and Oncology
2003 Alpha Omega Alpha Honor Medical Society, Duke University
2002 Duke Symposium Poster Presentation Award, Duke University
2001-2002 Clinical Research Fellow, National Institutes of Health

Professional Memberships

American Association of Women Radiologists
Member, 2008-present
American Brachytherapy Society
Member, 2008-present
American Society for Clinical Oncology
GU Symposium Program Committee Member, 2012-present
Member, 2005-present
American Society for Radiation Oncology
Abstract Reviewer, 2012
Abstract Reviewer, 2011
Abstract Reviewer, 2010
Member, 2005-present
American Society Therapeutic Radiology & Oncology
Health Services Research Committee Vice Chairman, 2012-present
Best Practices Committee Member, 2011-present
Member, 2009-present
Radiological Society of North America (RSNA)
Member - Public Information Advisors Network, 12/2010
Member, 9/2006-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Smith GL, Jiang J, Buchholz TA, Xu Y, Hoffman KE, Giordano SH, Hunt KK, Smith BD. Benefit of adjuvant brachytherapy versus external beam radiation for early breast cancer: Impact of patient stratification on breast preservation. Int J Radiat Oncol Biol Phys. In Press.
2. Mahmood U, Pugh TJ, Frank SJ, Levy LB, Walker GV, Haque W, Koshy M, Graber W, Swanson D, Hoffman KE, Kuban DA, Lee AK. Declining use of brachytherapy for the treatment of prostate cancer. Brachytherapy. In Press.
3. Aizer A, Chen MH, McCarthy E, Mendu M, Koo S, Wilhite T, Graham P, Choueiri T, Hoffman KE, Martin N, Hu J, Nguyen P. Martial Status and Survival in Patients with Cancer. J Clin Oncol. In Press.
4. MacDermed DM, Houtman KM, Thang SH, Allen PK, Caudle AS, Gainer SM, Hunt KK, Perkins GP, Shaitelman SF, Smith BD, Strom EA, Tereffe W, Woodward WA, Buchholz TA, Hoffman KE. Therapeutic Radiation Dose Delivered to the Low Axilla during Whole Breast Radiotherapy in the Prone Position: Implications for Targeting the Undissected Axilla. PRO. In Press.
5. Cerne JZ, McGuire SE, Grant SR, Munsell MF, Lee AK, Kudchadker RJ, Choi SL, Mahmood U, Hoffman KE, Pugh TJ, Frank SJ, Kuban DA. Factors associated with improved biochemical response to neoadjuvant androgen deprivation therapy before definitive radiation therapy in prostate cancer patients. Prostate Cancer Prostatic Dis. e-Pub 8/13/2013. PMID: 23939133.
6. Beard CJ, Travis LB, Chen MH, Arvold ND, Nguyen PL, Martin NE, Kuban DA, Ng AK, Hoffman KE. Outcomes in stage I testicular seminoma: A population-based study of 9193 patients. Cancer 119(15):2771-7, 8/1/2013. e-Pub 4/30/2013. PMID: 23633409.
7. Barocas DA, Chen V, Cooperberg M, Goodman M, Graff J, Greenfield S, Hamilton A, Hoffman KE, Kaplan S, Koyama T, Morgans A, Phillips S, Resnick M, Stroup A, Wu XC, Penson DF. Using a population-based observational cohort study to address difficult comparative effectiveness research questions: The CEASAR study. Journal of Comparative Effectiveness Research 2(4):445-460, 7/2013.
8. Efstathiou JA, Nassif DS, McNutt TR, Bogardus CB, Bosch W, Carlin J, Chen RC, Chou H, Eggert D, Fraass BA, Goldwein J, Hoffman KE, Hotz K, Hunt M, Kessler M, Lawton CA, Mayo C, Michalski JM, Mutic S, Potters L, Rose CM, Sandler HM, Sharp G, Tomé W, Tran PT, Wall T, Zietman AL, Gabriel PE, Bekelman JE. Practice-Based Evidence to Evidence-Based Practice: Building the National Radiation Oncology Registry. J Oncol Pract 9(3):e90-e95, 5/1/2013. PMID: 23942508.
9. Wang X, Zhang X, Li X, Amos RA, Shaitelman SF, Hoffman K, Howell R, Salehpour M, Zhang SX, Sun TL, Smith B, Tereffe W, Perkins GH, Buchholz TA, Strom EA, Woodward WA. Accelerated Partial-Breast Irradiation Using Intensity-Modulated Proton Radiotherapy: Do Uncertainties Outweigh Potential Benefits? Br J Radiol. e-Pub 5/2013. PMID: 23728947.
10. Pugh TJ, Frank SJ, Achim M, Kuban DA, Lee AK, Hoffman KE, McGuire SE, Swanson DA, Kudchadker R, Davis JW. Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: Implications for prostate brachytherapy. Brachytherapy 12(3):204-9, May-Jun, 5/2013. e-Pub 6/2012. PMID: 22673704.
11. Parekh A, Chen MH, D'Amico AV, Dosoretz DE, Ross R, Salenius S, Graham PL, Beckman JA, Beard CJ, Choueiri TK, Ennis RD, Hoffman KE, Hu JC, Ma J, Martin NE, Nguyen PL. Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer. Brachytherapy. e-Pub 5/2013. PMID: 23651926.
12. Weksberg DC, Allen PK, Hoffman KE, Litton JK, Strom EA, Shah RR, Kuerer HM, Hunt KK, Buchholz TA, Mittendorf EA. Outcomes and Predictive Factors for Salvage Therapy After Local-Regional Recurrence Following Neoadjuvant Chemotherapy and Breast Conserving Therapy. Ann Surg Oncol. e-Pub 5/2013. PMID: 23720073.
13. Bian SX, Kuban DA, Levy LB, Oh J, Castle KO, Pugh TJ, Choi S, McGuire SE, Nguyen QN, Frank SJ, Nguyen PL, Lee AK, Hoffman KE. Addition of short-term androgen deprivation therapy to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate cancer. Ann Oncol, Indian Excerpted Edition 4(2), 4/2013.
14. Hoffman KE, Niu J, Giordano SH, Ho V, Smith BD. Prostate Cancer Treatment Patterns in the State of Texas, 2004-2007. TPHA 65(2):36-42, 4/2013.
15. Castle KO, Hoffman KE, Levy LB, Lee AK, Choi S, Nguyen QN, Frank SJ, Pugh TJ, McGuire SE, Kuban DA. Is Androgen Deprivation Therapy Necessary in All Intermediate Risk Prostate Cancer Patients Treated in the Dose Escalation Era? Int J Radiat Oncol Biol Phys 85(3):693-9, 3/2013. e-Pub 7/2012. PMID: 22836052.
16. Mittendorf EA, Buchholz TA, Tucker SL, Meric-Bernstam F, Kuerer HM, Gonzalez-Angulo AM, Bedrosian I, Babiera GV, Hoffman K, Yi M, Ross MI, Hortobagyi GN, Hunt KK. Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy. Ann Surg 257(2):173-9, 2/2013. PMID: 23291658.
17. McGuire SE, Lee AK, Cerne JZ, Munsell MF, Levy LB, Kudchadker RJ, Choi SL, Nguyen QN, Hoffman KE, Pugh TJ, Frank SJ, Corn PG, Logothetis CJ, Kuban DA. PSA Response to Neoadjuvant Androgen Deprivation Therapy Is a Strong Independent Predictor of Survival in High-Risk Prostate Cancer in the Dose-Escalated Radiation Therapy Era. Int J Radiat Oncol Biol Phys 85(1):e39-46, 1/2013. e-Pub 10/2012. PMID: 23102837.
18. Parekh A, Chen MH, Hoffman KE, Choueiri TK, Hu JC, Bennett CL, Kattan MW, Sartor O, Stein K, Graham PL, D'Amico AV, Nguyen PL. Reduced Penile Size and Treatment Regret in Men With Recurrent Prostate Cancer After Surgery, Radiotherapy Plus Androgen Deprivation, or Radiotherapy Alone. Urology 81(1):130-5, 1/2013. PMID: 23273077.
19. Parekh A, Graham PL, D'Amico AV, Nguyen PL, Chen MH, Hoffman KE, Choueiri TK, Hu JC, Bennett CL, Kattan MW, Sartor O, Stein K. Reply. Urology 81(1):134-5, 1/2013. PMID: 23273079.
20. Arvold ND, Catalano PJ, Sweeney CJ, Hoffman KE, Nguyen PL, Balboni TA, Fosså SD, Travis LB, Beard CJ. Barriers to the Implementation of Surveillance for Stage I Testicular Seminoma. Int J Radiat Oncol Biol Phys 84(2):383-9, 10/2012. e-Pub 2/2012. PMID: 22349043.
21. Bian SX, Kuban DA, Levy LB, Oh J, Castle KO, Pugh TJ, Choi S, McGuire SE, Nguyen QN, Frank SJ, Nguyen PL, Lee AK, Hoffman KE. Addition of short-term androgen deprivation therapy to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate cancer. Ann Oncol 23(9):2346-52, 9/2012. e-Pub 2/2012. PMID: 22357249.
22. Jhaveri PM, Sun Z, Ballas L, Followill DS, Hoffman KE, Jiang J, Smith BD. Emergence of Integrated Urology-Radiation Oncology Practices in the State of Texas. Int J Radiat Oncol Biol Phys 84(1):15-9, 9/2012. e-Pub 7/2012. PMID: 22789491.
23. Holmes JA, Wang AZ, Hoffman KE, Hendrix LH, Rosenman JG, Carpenter WR, Godley PA, Chen RC. Is Primary Prostate Cancer Treatment Influenced by Likelihood of Extraprostatic Disease? A Surveillance, Epidemiology and End Results Patterns of Care Study. Int J Radiat Oncol Biol Phys 84(1):88-94, 9/2012. e-Pub 1/2012. PMID: 22300560.
24. Albert JM, Liu DD, Shen Y, Pan IW, Shih YC, Hoffman KE, Buchholz TA, Giordano SH, Smith BD. Nomogram to Predict the Benefit of Radiation for Older Patients With Breast Cancer Treated With Conservative Surgery. J Clin Oncol 30(23):2837-43, 8/2012. e-Pub 6/2012. PMCID: PMC3410401.
25. Caudle AZ, Hunt KK, Mittendorf EA, Tucker SL, Hoffman KE, Gainer SM, Lucci A, Kuerer HM, Meric-Bernstam F, Babiera G, Sahin AA, Shah RR. American College of Surgeons Oncology Group (ACOSOG) Z0011: Impact on Surgeon Practice Patterns. Ann Surg Oncol. e-Pub 7/2012.
26. Nguyen PL, Chen MH, Hoffman KE, Chen RC, Hu JC, Bennett CL, Kattan MW, Sartor O, Stein K, D'Amico AV. Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer. BJU Int 110(2):201-205, 7/2012. e-Pub 11/2011. PMID: 22085233.
27. Kim MM, Hoffman KE, Levy LB, Frank SJ, Pugh TJ, Choi S, Nguyen QN, McGuire SE, Lee AK, Kuban DA. Prostate cancer-specific mortality after definitive radiation therapy: Who dies of disease? Eur J Cancer 48(11):1664-71, 7/2012. e-Pub 2/2012. PMID: 22336663.
28. Pinnix C, Perkins GH, Strom EA, Tereffe W, Woodward W, Oh JL, Arriaga L, Munsell MF, Kelly P, Hoffman KE, Smith BD, Buchholz TA, Yu TK. Topical Hyaluronic Acid vs. Standard of Care for the Prevention of Radiation Dermatitis After Adjuvant Radiotherapy for Breast Cancer: Single-Blind Randomized Phase III Clinical Trial. Int J Radiat Oncol Biol Phys 83(4):1089-94, 7/2012. e-Pub 12/2011. PMID: 22172912.
29. Hoffman KE, Mittendorf EA, Buchholz TA. Optimising radiation treatment decisions for patients who receive neoadjuvant chemotherapy and mastectomy. Lancet Oncol 13(6):e270-6, 6/2012. PMID: 22652235.
30. Akay CL, Meric-Bernstam F, Hunt KK, Grubbs EG, Bedrosian I, Tucker SL, Kuerer HM, Hoffman KE, Babiera GV, Strom EA, Buchholz TA, Mittendorf EA. Evaluation of the MD Anderson prognostic index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy. Ann Surg Oncol 19(3):901-7, 3/2012. e-Pub 8/2011. PMID: 21861223.
31. Nguyen PL, Chen MH, Beckman JA, Beard CJ, Martin NE, Choueiri TK, Hu JC, Hoffman KE, Dosoretz DE, Moran BJ, Salenius SA, Braccioforte MH, Kantoff PW, D'Amico AV, Ennis RD. Influence of androgen deprivation therapy (ADT) on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure (CHF) or myocardial infarction (MI). Int J Radiat Oncol Biol Phys 82(4):1411-6, 3/2012. e-Pub 6/2011. PMID: 21708431.
32. Wang X, Pan T, Pinnix C, Zhang SX, Salehpour M, Sun TL, Gladish G, Strom EA, Perkins GH, Tereffe W, Woodward W, Hoffman KE, Buchholz TA, Yu TK. Cardiac motion during deep-inspiration breath-hold: implications for breast cancer radiotherapy. Int J Radiat Oncol Biol Phys 82(2):708-14, 2/2012. e-Pub 3/2011. PMID: 21444161.
33. Hoffman KE, Neville BA, Mamon HJ, Kachnic LA, Katz MS, Earle CC, Punglia RS. Adjuvant therapy for elderly patients with resected gastric adenocarcinoma: population-based practices and treatment effectiveness. Cancer 118(1):248-57, 1/2012. e-Pub 6/2011. PMCID: PMC3178711.
34. Kim MM, Hoffman KE, Levy LB, Frank SJ, Pugh TJ, Choi S, Nguyen QN, McGuire SE, Lee AK, Kuban DA. Improvement in prostate cancer survival over time: a 20-year analysis. Cancer J 18(1):1-8, Jan-Feb, 1/2012. PMID: 22290249.
35. Caudle AS, Yu TK, Tucker SL, Bedrosian I, Litton JK, Gonzalez-Angulo AM, Hoffman K, Meric-Bernstam F, Hunt KK, Buchholz TA, Mittendorf EA. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res 14(3):R83, 2012. e-Pub 5/2012. PMCID: PMC3446346.
36. Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A, Beckman JA, Choueiri TK. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 306(21):2359-66, 12/2011. PMID: 22147380.
37. Shirvani SM, Pan IW, Buchholz TA, Shih YC, Hoffman KE, Giordano SH, Smith BD. Impact of evidence-based clinical guidelines on the adoption of postmastectomy radiation in older women. Cancer 117(20):4595-605, 10/2011. e-Pub 6/2011. PMID: 21710653.
38. Caudle AS, Hunt KK, Kuerer HM, Meric-Bernstam F, Lucci A, Bedrosian I, Babiera GV, Hwang RF, Ross MI, Feig BW, Hoffman K, Litton JK, Sahin AA, Yang W, Hortobagyi GN, Buchholz TA, Mittendorf EA. Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial. Ann Surg Oncol 18(9):2407-12, 9/2011. PMID: 21327455.
39. Wang X, Amos RA, Zhang X, Taddei PJ, Woodward WA, Hoffman KE, Yu TK, Tereffe W, Oh J, Perkins GH, Salehpour M, Zhang SX, Sun TL, Gillin M, Buchholz TA, Strom EA. External-beam accelerated partial breast irradiation using multiple proton beam configurations. Int J Radiat Oncol Biol Phys 80(5):1464-72, 8/2011. e-Pub 8/2010. PMID: 20708848.
40. Mak RH, McCarthy EP, Das P, Hong TS, Mamon HJ, Hoffman KE. Adoption of preoperative radiation therapy for rectal cancer from 2000 to 2006: a surveillance epidemiology and end results patterns of care study. Int J Radiat Oncol Biol Phys 80(4):978-84, 7/2011. e-Pub 10/2010. PMID: 20961695.
41. Albert JM, Buzdar AU, Guzman R, Allen PK, Strom EA, Perkins GH, Woodward WA, Hoffman KE, Tereffe W, Hunt KK, Buchholz TA, Oh JL. Prospective randomized trial of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus paclitaxel and FAC (TFAC) in patients with operable breast cancer: impact of taxane chemotherapy on locoregional control. Breast Cancer Res Treat 128(2):421-7, 7/2011. e-Pub 5/2011. PMID: 21553292.
42. Nguyen PL, Gu X, Lipsitz SR, Choueiri TK, Choi WW, Lei Y, Hoffman KE, Hu JC. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol 29(12):1517-24, 4/2011. e-Pub 3/2011. PMID: 21402604.
43. Nguyen PL, Chen MH, Choueiri TK, Hoffman KE, Hu JC, Martin NE, Beard CJ, Dosoretz DE, Moran BJ, Katin MJ, Braccioforte MH, Ross R, Salenius SA, Kantoff PW, D'Amico AV. Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size. Int J Radiat Oncol Biol Phys 79(5):1318-22, 4/2011. e-Pub 6/2010. PMID: 20605366.
44. Hoffman KE, Nguyen PL, Chen MH, Chen RC, Choueiri TK, Hu JC, Kuban DA, D'Amico AV. Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. J Urol 185(1):116-20, 1/2011. e-Pub 11/2010. PMID: 21074194.
45. Nguyen PL, Chen RC, Hoffman KE, Trofimov A, Efstathiou JA, Coen JJ, Shipley WU, Zietman AL, Talcott JA. Rectal dose-volume histogram parameters are associated with long-term patient-reported gastrointestinal quality of life after conventional and high-dose radiation for prostate cancer: a subgroup analysis of a randomized trial. Int J Radiat Oncol Biol Phys 78(4):1081-5, 11/2010. e-Pub 3/2010. PMID: 20207497.
46. Ahove DA, Hoffman KE, Hu JC, Choueiri TK, D'Amico AV, Nguyen PL. Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence? Implications for a risk-adapted follow-up strategy. Urology 76(5):1201-5, 11/2010. e-Pub 8/2010. PMID: 20709376.
47. Walker GV, Smith GL, Perkins GH, Oh JL, Woodward W, Yu TK, Hunt KK, Hoffman K, Strom EA, Buchholz TA. Population-based analysis of occult primary breast cancer with axillary lymph node metastasis. Cancer 116(17):4000-6, 9/2010. PMID: 20564117.
48. Hoffman KE, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin MJ, Ross R, D'Amico AV. Prostate-cancer specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer. Cancer 116(11):2590-5, 6/2010. e-Pub 3/2010. PMID: 20310055.
49. Hoffman KE, Nguyen PL, Ng AK, D'Amico AV. Prostate cancer screening in men 75 years old or older: an assessment of self-reported health status and life expectancy. J Urol 183(5):1798-802, 5/2010. e-Pub 3/2010. PMID: 20299039.
50. Nguyen PL, Chen MH, Beard CJ, Suh WW, Choueiri TK, Efstathiou JA, Hoffman KE, Loffredo M, Kantoff PW, D'Amico AV. Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence. Cancer 116(3):610-5, 2/2010. e-Pub 12/2009. PMID: 19957321.
51. Hoffman KE, Yock TI. Radiation therapy for pediatric central nervous system tumors. J Child Neurol 24(11):1387-96, 11/2009. PMID: 19841427.
52. Hoffman KE, McCarthy EP, Recklitis CJ, Ng AK. Psychological distress in long-term survivors of adult-onset cancer: results from a national survey. Arch Intern Med 169(14):1274-81, 7/2009. PMID: 19636028.
53. Hong SH, Briggs J, Newman R, Hoffman K, Mendoza A, LeRoith D, Helman L, Yakar S, Khanna C. Murine osteosarcoma primary tumor growth and metastatic progression is maintained after marked suppression of serum insulin-like growth factor I. Int J Cancer 124(9):2042-9, 5/2009. PMID: 19132750.
54. Nguyen PL, Chen MH, Hoffman KE, Katz MS, D'Amico AV. Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era. Int J Radiat Oncol Biol Phys 74(1). e-Pub 3/2009. PMID: 19286330.
55. Hoffman KE, Chen MH, Punglia RS, Beard CJ, D'Amico AV. Influence of year of diagnosis, patient age, and sociodemographic status on recommending adjuvant radiation treatment for stage I testicular seminoma. J Clin Oncol 26(24):3937-42, 8/2008. PMID: 18711182.
56. Hoffman KE, Hong TS, Zietman AL, Russell AH. External beam radiation treatment for rectal cancer is associated with a decrease in subsequent prostate cancer diagnosis. Cancer 112(4):943-9, 2/2008. PMID: 18098220.
57. Hoffman KE, Derdak J, Bernstein D, Reynolds JC, Avila NA, Gerber L, Steinberg SM, Chrousos G, Mackall CL, Mansky PJ. Metabolic syndrome traits in long-term survivors of pediatric sarcoma. Pediatr Blood Cancer 50(2):341-6, 2/2008. PMID: 17918262.
58. Hoffman KE, Horowitz NS, Russell AH. Healing of vulvo-vaginal radionecrosis following revascularization. Gynecol Oncol 106(1):262-4, 7/2007. PMID: 17507081.
59. Mansky P, Arai A, Stratton P, Bernstein D, Long L, Reynolds J, Chen D, Steinberg SM, Lavende N, Hoffman K, Nathan PC, Parks R, Augustine E, Chaudhry U, Derdak J, Wiener L, Gerber L, Mackall C. Treatment late effects in long-term survivors of pediatric sarcoma. Pediatr Blood Cancer 48(2):192-9, 2/2007. PMID: 16642490.
60. Gerber LH, Hoffman K, Chaudhry U, Augustine E, Parks R, Bernard M, Mackall C, Steinberg S, Mansky P. Functional outcomes and life satisfaction in long-term survivors of pediatric sarcomas. Arch Phys Med Rehabil 87(12):1611-7, 12/2006. PMID: 17141641.
61. Rowe-Taitt CA, Golden JP, Feldstein MJ, Cras JJ, Hoffman KE, Ligler FS. Array biosensor for detection of biohazards. Biosens Bioelectron 14(10-11):785-94, 1/2000. PMID: 10945453.
62. Rowe-Taitt CA, Hazzard JW, Hoffman KE, Cras JJ, Golden JP, Ligler FS. Simultaneous detection of six biohazardous agents using a planar waveguide array biosensor. Biosens Bioelectron 15(11-12):579-89, 2000. PMID: 11213218.
63. Bart JC, Judd LL, Hoffman KE, Wilkins AM, Kusterbeck AW. Application of a portable immunosensor to detect the explosives TNT and RDX in groundwater samples. Environmental Science Technology 31(5):1505-1511, 4/1997.

Invited Articles

1. Bian SX, Hoffman KE. Management of Prostate Cancer in Elderly Men. Semin Radiat Oncol 23(3):198-205, 7/2013. PMID: 23763886.
2. Pugh TJ, Nguyen BN, Kanke JE, Johnson JL, Hoffman KE. Radiation Therapy Modalities in Prostate Cancer. J Natl Compr Canc Netw 11(4):414-21, 4/1/2013. PMID: 23584344.
3. Hoffman KE, Kuban DA. Commentary on Lymph-node Positive Prostate Cancer: The Benefit of Local Therapy. Oncology 27(7), 2013.
4. Hoffman KE. Management of Older Men with Clinically Localized Prostate Cancer: The Significance of Advanced Age and Comorbidity. Semin Radiat Oncol 22(4):284-94, 10/2012. PMID: 22985811.
5. Nguyen PL, Hoffman KE. Adjuvant vs. Salvage Radiation for pT3 or Margin Positive Prostate Cancer. AUA News 16(10):18-20, 9/2011.
6. Hoffman KE, Nguyen PL. The Debate over Prostate Cancer Screening Guidelines. Virtual Mentor 13(1):10-15, http://virtualmentor.ama-assn.org/2011/01/ccas2- 1101.html, 1/2011.
7. Hoffman KE, Buchholz TA. How Improved Local-Regional Therapy Impacts Survival. Current Breast Cancer Reports 2(2). e-Pub 4/2010.

Editorials

1. Hoffman KE, Whitman GJ. Commentary on: Screening Breast MR Imaging in Women with a History of Chest Irradiation. Breast Diseases: A Year Book Quarterly 23(2), 7/2012.
2. Hoffman KE. Commentary on: Long-Term Survival Among Patients with Hodgkin's Lymphoma who Developed Breast Cancer. Breast Diseases: A Year Book Quarterly 22(4):364-365, 2011.
3. Hoffman KE. Commentary on: Transitioning to Breast Cancer Survivorship: Perspectives of Patients, Cancer Specialists, and Primary Care Providers. Breast Diseases: A Year Book Quarterly 21(2):125-126, 7/2010.
4. Hoffman KE, Harris JR. Commentary on: Prognostic value of triple-negative phenotype at the time of locally recurrent conservatively treated breast cancer. Breast Diseases: A Year Book Quarterly 20(2):172-174, 7/2009.

Abstracts

1. Hoffman KE, Kim J, Davis JW, Choi S, Pettaway C, Lee AK, Domain D, Levy L, Madsen LT, Kuban DA. Barriers to Active Surveillance as a Treatment Choice for Prostate Cancer. I.J. Radiation Oncology, Biology, Physics 81(2):S141-S142, 10/2011.
2. Domain D, Hoffman KE, Madsen LT, Pettaway CA, Kim J, Davis JW, Lee AK, Pisters L, Levy L, Kuban DA. Clinical Trial Enrollment in a Multidisciplinary Prostate Cancer Clinic. I.J. Radiation Oncology, Biology, Physics 81(2):S565, 10/2011.
3. Hoffman KE, Madsen LT, Levy L, Pettaway C, Pisters L, Choi S, Kim J, Davis JW, Ward JF, Kuban DA. Prostate Cancer Treatment Selection after Counseling in a Multidisciplinary Prostate Cancer Clinic. I.J. Radiation, Oncology, Biology, Physics 81(2):S563-S564, 10/2011.
4. Albert JM, Buzdar AU, Guzman R, Allen PK, Strom EA, Perkins GH, Woodward WA, Hoffman KE, Tereffe W, Hunt KK, Buchholz TA, Oh JL. Prospective randomized trial of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus paclitaxel and FAC (TFAC) in patients with operable breast cancer: impact of taxane chemotherapy on locoregional control. Breast Cancer Res Treat. 128(2):421-7, 7/2011. PMID: 21553292.
5. Nguyen PL, Chen M, Chen RC, Hoffman KE, Hu JC, Bennett CL, Kattan MW, Sartor O, Stein K, D’Amico AV. Comorbidity and Treatment Regret in Men with Recurrent Prostate Cancer, 2/2011.
6. Hoffman KE, Chen M, Nguyen PL, Bennett CL, Sartor AO, Stein K, Kuban DA, D'Amico AV. Factors Associated with a Delay in Diagnosis of Recurrent Prostate Cancer After Radical Prostatectomy. 2/2011.
7. Kim MM, Hoffman KE, Levy LB, Master P, Frank SJ, Choi S, Nguyen QN, McGuire SE, Lee AK, Kuban DA. Improvement in Prostate Cancer Outcomes Over Time: A Twenty-Year Analysis. I.J. Radiation Oncology, Biology, Physics 78(3):S191, 11/2010.
8. Beard CJ, Chen M, Arvold ND, Nguyen PL, Ng AK, Hoffman KE. Long-Term Survival and Competing Causes of Death in Men with Stage I Seminoma. I.J. Radiation Oncology, Biology, Physics 78(3):S60, 11/2010.
9. Hoffman KE, Symmans WF, Oh JL, Welela T, Yu TK, Perkins GH, Strom EA, Gonzalez-Angulo AM, Buchholz TA, Woodward WA. Pathologic features Predicting for High Rates of Local-Regional Recurrence after Neoadjuvant Chemotherapy and Radiation Therapy for Breast Cancer. I.J. Radiation Oncology, Biology, Physics 78(3):S97, 11/2010.
10. Arvold ND, Catalano PJ, Sweeney CJ, Hoffman KE, Nguyen PL, Balboni TA, Fosså SD, Travis LB, Beard CJ. Patterns of care for stage I seminoma: a survey of American radiation oncologists. I.J. Radiation Oncology, Biology, Physics 78(3):S193, 11/2010.
11. Kuban DA, Nogueras-Gonzalez GM, Hamblin L, Lee AK, Choi S, Frank SJ, Nguyen QN, Hoffman KE, McGuire SE, Munsell MF. Preliminary Report of a Randomized Dose Escalation Trial for Prostate Cancer Using Hypofractionation. I.J. Radiation Oncology, Biology, Physics 78(3):S58, 11/2010.
12. McGuire SE, Levy LB, Settle SH, Choi S, Nguyen QN, Hoffman KE, Frank SJ, Lee AK, Kuban DA. PSA Response to Neoadjuvant Androgen Suppression Therapy Prior to High Dose Radiotherapy Predicts Survival in Clinically Localized High Risk Prostate Cancer. I.J. Radiation Oncology, Biology, Physics 78(3):S124, 11/2010.
13. Nguyen Q, Levy LB, Lee AK, Choi S, Frank SJ, Hoffman KE, McGuire S, Kuban DA. Risk Factors Predicting Failure And Prostate Cancer Mortality In High Risk Prostate Cancer Patients Treated With Definitive External Beam Radiation Therapy. I.J. Radiation Oncology, Biology, Physics 78(3):S125, 11/2010.
14. Nguyen PL, Chen M, Dosoretz DE, Moran BJ, Salenius SA, Braccioforte MH, Beard CJ, Hoffman KE D’Amico AV, Ennis RD. The Adverse Impact of Androgen Deprivation Therapy on All-Cause Mortality in Men with High-Risk Prostate Cancer and a History of Congestive Heart Failure (CHF) or Myocardial Infarction (MI). I.J. Radiation Oncology, Biology, Physics 78(3):A350, 11/2010.
15. Hoffman KE. Medicare Claims Data: Rapid Answers to Big Questions, 10/2010.
16. Morikawa LK, Rajat K, Kanke J, Choi S, Nguyen QN, McGuire S, Hoffman K, Frank SJ, Lee A, Kuban DA. Endorectal balloon in Post-Operative Prostate Cancer Patients: Who Benefits From It?, 5/2010.
17. Morikawa LK, Levy LB, Choi S, Nguyen QN, McGuire S, Hoffman K, Frank SJ, Lee A, Kuban DA. Relationship Between PSA Failure and Death From Prostate Cancer After Radical External Beam Radiation Therapy, 5/2010.
18. Walker GV, Smith GL, Allen P, Perkins GH, Oh JL, Woodward WA, Yu TK, Hunt KK, Hoffman K, Strom EA, Buchholz TA. Population-Based Analysis of Occult Primary Breast Cancer with Axillary Nodal Metastasis. Oncology 24(4 Suppl 3):2, 4/2010.
19. Hoffman KE, Chen M, Nguyen PL, D'Amico AV. Post-prostatectomy Radiation Therapy in the United States: Patterns of Care. International Journal of Radiation Oncology, Biology, Physics 75(3, Supplement):S90, 11/2009.
20. Hoffman KE, Abi-Raad R, Ancukiewicz M, Yeh E, Ryan P, Schapira L, Younger J, Smith B, Kuter I, Taghian A. Impact of Interstitial Fluid Pressure, Tumor Oxygenation, and Chemotherapy Drug Sequencing on Response to Neoadjuvant Chemotherapy and on Long-Term Local Control in Women Treated for Locally Advanced Breast Cancer. I.J. Radiation Oncology, Biology, Physics 69(3):S61-S62, 11/2007.

Book Chapters

1. Patterson ML, Davis JW, Kim JE, Hoffman KE, Osai WE, Kuban DA. Guidelines for Long-term Management of Genitourinary Cancer Survivors. In: The MD Anderson Cancer Center Survivorship Textbook. In Press.
2. Kuban DA, Hoffman KE, Corn P, Pettaway C. Prostate Cancer. In: 60 Years of Survival Outcomes at the University of Texas, MD Anderson Cancer Center, 35-43, 2013.
3. Bart JC, Judd LL, Hoffman KE, Wilkins AM, Charles PT, Kusterbeck AQ. Detection and Quantitation of the Explosives 2, 4, 6-Trinitrotoluene and Hexahydro-1, 3, 5-triazine in Groundwater Using a Continuous Flow Immunosensor. In: Immunochemical Technology for Environmental Applications: Washington, DC, 210-220, 1997.

Last updated: 8/28/2013